MDCT appearance of gastrointestinal stromal tumors after therapy with imatinib mesylate

被引：14
|
作者：
Warakaulle, DR [1 ]
Gleeson, F [1 ]
机构：
[1] Churchill Hosp, Dept Radiol, Oxford OX3 7LJ, England
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2006年 / 186卷 / 02期
关键词：
CT; gastrointestinal imaging; gastrointestinal stromal tumors; imatinib mesylate; oncologic imaging;
D O I：
10.2214/AJR.04.1516
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OBJECTIVE. Our objective was to determine the MDCT appearance of gastrointestinal stromal tumors (GISTs) after treatment with imatinib mesylate. CONCLUSION. Cystic changes within primary and metastatic GISTs seen on MDCT in patients after imatinib mesylate therapy are evidence of disease response. Calcification may also occur in lesions that respond to therapy.
引用
收藏
页码：510 / 515
页数：6
相关论文
共 50 条
  • [1] Imaging of Gastrointestinal Stromal Tumors before and after Imatinib Mesylate Therapy
    Shankar, S.
    Dundamadappa, S. K.
    Karam, A. R.
    Stay, R. M.
    van Sonnenberg, E.
    ACTA RADIOLOGICA, 2009, 50 (08) : 837 - 844
  • [2] Treatment of localized anorectal gastrointestinal stromal tumors with preoperative imatinib mesylate therapy
    Wang, W.
    Luo, S.
    Chen, W.
    Kang, L.
    Deng, Y.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S412 - S412
  • [3] Imatinib mesylate therapy in patients with gastrointestinal stromal tumors and impaired liver function
    Bauer, S
    Hagen, V
    Pielken, HJ
    Bojko, P
    Seeber, S
    Schütte, J
    ANTI-CANCER DRUGS, 2002, 13 (08) : 847 - 849
  • [4] Imatinib Mesylate: Targeted Therapy of Gastrointestinal Stromal Tumor
    Trent, Jonathan C.
    Dupart, Jheri
    Zhang, Wei
    CURRENT CANCER THERAPY REVIEWS, 2005, 1 (01) : 93 - 108
  • [5] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    Demetri, GD
    von Mehren, M
    Blanke, CD
    Van den Abbeele, AD
    Eisenberg, B
    Roberts, PJ
    Heinrich, MC
    Tuveson, DA
    Singer, S
    Janicek, M
    Fletcher, JA
    Silverman, SG
    Silberman, SL
    Capdeville, R
    Kiese, B
    Peng, B
    Dimitrijevic, S
    Druker, BJ
    Corless, C
    Fletcher, CDM
    Joensuu, H
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07): : 472 - 480
  • [6] Gastrointestinal stromal tumors: Overview of pathologic features, molecular biology, and therapy with imatinib mesylate
    Koh, JS
    Trent, J
    Chen, L
    El-Naggar, A
    Hunt, K
    Pollock, R
    Zhang, W
    HISTOLOGY AND HISTOPATHOLOGY, 2004, 19 (02) : 565 - 574
  • [7] Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate
    Jacopo Giuliani
    Andrea Bonetti
    ChineseJournalofCancerResearch, 2013, 25 (05) : 486 - 487
  • [8] Surgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy.
    Rutkowski, P
    Nowecki, Z
    Nyckowski, P
    Dziewirski, W
    Nasierowska-Guttmejer, A
    Grzesiakowska, U
    Michej, W
    Krawczyk, M
    Ruka, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 825S - 825S
  • [9] Gastrointestinal stromal tumors and second primary malignancies before and after the introduction of imatinib mesylate
    Giuliani, Jacopo
    Bonetti, Andrea
    CHINESE JOURNAL OF CANCER RESEARCH, 2013, 25 (05) : 486 - 487
  • [10] Gastrointestinal stromal tumor with metastases in an adult woman treated with imatinib mesylate:: MDCT findings
    Busalacchi, PJB
    de la Callel, MAC
    Torroba, A
    del Río, ST
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 184 (03) : S58 - S61
12345